Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
AC-262 (Accadrine), (10mg/capsule) 60 Capsules
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
AC-262 (Accadrine) is a selective androgen receptor modulator (SARM) characterised by tissue-selective binding at the androgen receptor (AR). Research interest centers on its differential activation profile across musculoskeletal versus other AR-expressing tissue models, distinguishing it from non-selective steroidal AR ligands. Research applications include AR binding-affinity assays, tissue-selectivity comparison studies, and SARM structure-activity relationship investigation.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C18H18N2O |
|---|---|
| Synonyms | AC-262536, 870888-46-3, UNII-U8VS41J5O6, U8VS41J5O6 |
| Molar Mass | 278.3 g/mol |
| CAS Number | 870888-46-3 |
| PubChem CID | 44512434 |
| Total Compound Content | 600mg (10mg per capsule) |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
What distinguishes AC-262 from steroidal androgen receptor agonists in receptor-binding research?
AC-262 is a non-steroidal arylpropionamide-derived androgen receptor (AR) ligand that differs structurally from steroid-based AR agonists. This distinct chemical scaffold produces unique receptor conformations upon binding, influencing co-regulator recruitment and downstream transcriptional activity. As a result, AC-262 is frequently used in comparative receptor pharmacology and structure-activity relationship (SAR) studies investigating how ligand architecture affects AR activation, signalling bias, and gene-expression outcomes.
How is AC-262's tissue selectivity evaluated in research models?
Tissue selectivity is typically assessed by comparing AR-mediated transcriptional activity across multiple AR-expressing experimental systems using reporter-gene assays, gene-expression profiling, and pathway-activation studies. Differences in potency, efficacy, and transcriptional output between model systems provide insight into selective AR modulation. Combining these functional measurements with receptor-binding data helps distinguish effects related to receptor affinity from those arising through downstream signalling and co-regulator interactions.
What assay formats are commonly used to evaluate AC-262 androgen receptor activity?
Standard approaches include competitive receptor-binding assays to determine relative AR affinity and cell-based transactivation assays utilizing AR-responsive reporter constructs to quantify functional activity. Additional studies often incorporate co-activator recruitment assays, gene-expression analysis, and comparative ligand profiling to characterize receptor activation patterns. Together, these methods provide a comprehensive assessment of receptor binding, signalling efficacy, and selective androgen receptor modulation.
-
-
-
SALE
-
SALE
-
SALE
-
SALE
-
SALE
-
SALE
